Cas no 181695-72-7 (Valdecoxib)

Valdecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor, primarily used as a nonsteroidal anti-inflammatory drug (NSAID) for managing pain and inflammation. Its mechanism of action involves preferential inhibition of COX-2 over COX-1, reducing prostaglandin synthesis at inflammatory sites while minimizing gastrointestinal side effects associated with non-selective NSAIDs. Valdecoxib exhibits high bioavailability and rapid onset of action, making it effective for acute pain relief, including postoperative pain and osteoarthritis. Its selectivity contributes to a lower risk of gastric ulcers compared to traditional NSAIDs. However, its use requires careful consideration of cardiovascular risks, as with other COX-2 inhibitors. The compound is typically administered orally in tablet form.
Valdecoxib structure
Valdecoxib structure
Product Name:Valdecoxib
CAS No:181695-72-7
MF:C16H14N2O3S
MW:314.358962535858
MDL:MFCD00950568
CID:66184
PubChem ID:329823753
Update Time:2025-06-07

Valdecoxib Chemical and Physical Properties

Names and Identifiers

    • VALDECOXIB
    • 4-(5-METHYL-3-PHENYL-4-ISOXAZOLYL)BENZENESULFONAMIDE
    • AKOS 92130
    • BEXTRA
    • BEXTRA(VALDECOXIB)
    • Bextra, 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenefulfonamide
    • 4-(5-methyl-3-phenyl-oxazol-4-yl)benzenesulfonamide
    • Bextra, 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide
    • 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide
    • 4-(5-methyl-3-phenyl-4-isoxazolyl)-benzenesulfonamide
    • SC 65872
    • [14C]-Valdecoxib
    • 4-(4-sulfamoylphenyl)-5-methyl-3-phenyl-isoxazole
    • 4-(5-methyl-3-phenylisoxazol-4-yl)benzensulfonamide
    • 4-[5-methyl-3-phenylisoxazol-4-yl ] benzenesulfonamide
    • Kudeq
    • Valdecoxib(R)
    • Valdyn
    • 4-(5-Methyl-3-phenyl-4-isooxazolyl)benzenesulfonamide
    • Valz
    • Valus
    • Valecoxib
    • Parecoxib Impurity 4
    • Valdecoxib Solution, 100ppm
    • 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
    • Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-
    • p-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide
    • LNPDTQAFDNKSHK-UHFFFAOYSA-N
    • 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide
    • COX
    • NCGC00095129-0
    • SPBio_000435
    • DTXCID4024226
    • C21552
    • BRD-K12994359-001-14-3
    • FT-0675755
    • SR-01000759421-4
    • CHEBI:63634
    • cid_119607
    • SCHEMBL3356
    • BRD-K12994359-001-02-8
    • Spectrum_001747
    • Spectrum5_001476
    • HMS1922J21
    • J-513600
    • CCG-39589
    • M01AH03
    • HMS3885O20
    • NSC-759846
    • Valdecoxib [USAN:INN:BAN]
    • s4049
    • MRF-0000216
    • MLS001424105
    • NCGC00095129-01
    • BSPBio_002721
    • Spectrum4_001129
    • UNM-0000305814
    • BCP02419
    • Spectrum2_000508
    • YM-974
    • NCGC00095129-06
    • SPECTRUM1504302
    • VLX
    • Spectrum3_001001
    • FT-0631199
    • VALDECOXIB [MART.]
    • ND-0214
    • Valdecoxib [USAN]
    • valdecoxibum
    • MLS001165699
    • Tox21_111438
    • HSDB 7302
    • HMS2051P07
    • CS-1674
    • KBio3_001941
    • SR-01000759421
    • DB00580
    • 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide
    • KBio2_004795
    • CHEMBL865
    • SC-65872
    • HMS3372D12
    • Q347613
    • MLS000759433
    • 181695-72-7
    • VALDECOXIB [WHO-DD]
    • SB19519
    • Tox21_111438_1
    • NSC 759846
    • AKOS000280920
    • 2919279Q3W
    • InChI=1/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20
    • D02709
    • 2aw1
    • AB00639996_10
    • Valdecoxib, analytical reference material
    • Valdecoxib (USAN/INN)
    • MFCD00950568
    • VALDECOXIB [INN]
    • HMS2232P23
    • KBio2_002227
    • KBio2_007363
    • DTXSID6044226
    • HMS3652I04
    • AMY31078
    • HMS3715L18
    • 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonamide
    • Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI)
    • GTPL2894
    • AC-120
    • NC00184
    • VALDECOXIB [HSDB]
    • NCGC00095129-02
    • J-011613
    • KBioGR_001617
    • 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide
    • AB00639996-08
    • SMR000466327
    • NS00009831
    • EX-A241
    • VALDECOXIB [ORANGE BOOK]
    • CAS-181695-72-7
    • KBioSS_002227
    • NSC759846
    • EN300-7393031
    • BDBM13063
    • SW197564-2
    • A812629
    • VALDECOXIB [VANDF]
    • VALDECOXIB [EMA EPAR]
    • 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide
    • Valdecoxib, >=98% (HPLC)
    • Pharmakon1600-01504302
    • VALDECOXIB [MI]
    • 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamide
    • MLS001195631
    • UNII-2919279Q3W
    • VALDECOXIB (MART.)
    • NCGC00095129-03
    • Valdecoxib-13C2, 15N
    • HMS3393P07
    • HY-15762
    • BRD-K12994359-001-18-4
    • DB-044435
    • Valdecoxib
    • MDL： MFCD00950568
    • Inchi： 1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)
    • InChI Key： LNPDTQAFDNKSHK-UHFFFAOYSA-N
    • SMILES： S(C1C=CC(=CC=1)C1=C(C)ON=C1C1C=CC=CC=1)(N)(=O)=O

Computed Properties

  • Exact Mass: 314.07300
  • Monoisotopic Mass: 314.07251349g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 5
  • Heavy Atom Count: 22
  • Rotatable Bond Count: 3
  • Complexity: 462
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 94.6
  • XLogP3: 2.6

Experimental Properties

  • Color/Form: Powder
  • Melting Point: 169.0 to 173.0 deg-C
  • Boiling Point: 481.2°C at 760 mmHg
  • Solubility: DMSO: >25mg/mL
  • PSA: 94.57000
  • LogP: 4.74550
  • λmax: 202(H2O)(lit.)
  • Merck: 9900

Valdecoxib Security Information

  • Symbol: GHS08 GHS09
  • Prompt：warning
  • Signal Word：Warning
  • Hazard Statement： H361d-H373-H410
  • Warning Statement： P273-P281-P501
  • Hazardous Material transportation number：NONH for all modes of transport
  • WGK Germany：3
  • Hazard Category Code： 63-48/22-51/53
  • Safety Instruction： 36/37-61
  • RTECS：DB2944030
  • Hazardous Material Identification： Xn N
  • Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
  • PackingGroup：III

Valdecoxib Customs Data

  • HS CODE：2935009090
  • Customs Data：

    China Customs Code:

    2935009090

    Overview:

    2935009090 Other sulphonates(Acyl)amine. VAT:17.0% Tax refund rate:9.0% Regulatory conditions:nothing MFN tariff:6.5% general tariff:35.0%

    Declaration elements:

    Product Name, component content, use to

    Summary:

    2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%

Valdecoxib Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI XIAN DING Biotechnology Co., Ltd.
V0133-200mg
Valdecoxib
 181695-72-7 98.0%(LC&N)
200mg
 ￥390.0 2022-06-09
SHANG HAI XIAN DING Biotechnology Co., Ltd.
V0133-1g
Valdecoxib
 181695-72-7 98.0%(LC&N)
1g
 ￥1390.0 2022-06-09
SHANG HAI XIAN DING Biotechnology Co., Ltd.
SN400-10mg
Valdecoxib
 181695-72-7 97%
10mg
 834CNY 2021-05-08
SHANG HAI XIAN DING Biotechnology Co., Ltd.
SN400-50mg
Valdecoxib
 181695-72-7 97%
50mg
 3510CNY 2021-05-08
SHANG HAI XIAN DING Biotechnology Co., Ltd.
SN400-5mg
Valdecoxib
 181695-72-7 97%
5mg
 490CNY 2021-05-08
SHANG HAI XIAN DING Biotechnology Co., Ltd.
B-FY320-100mg
Valdecoxib
 181695-72-7 97%
100mg
 162CNY 2021-05-08
Chemenu
CM190651-1g
4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
 181695-72-7 97%
1g
 $842 2021-08-05
TRC
V090000-5mg
Valdecoxib
 181695-72-7
5mg
 $ 64.00 2023-09-05
TRC
V090000-10mg
Valdecoxib
 181695-72-7
10mg
 $115.00 2023-05-17
TRC
V090000-25mg
Valdecoxib
 181695-72-7
25mg
 $ 230.00 2023-09-05

Valdecoxib Production Method

Valdecoxib Suppliers

Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:181695-72-7)Valdecoxib
Order Number:A812629
Stock Status:in Stock
Quantity:25g/100g
Purity:99%
Pricing Information Last Updated:Friday, 30 August 2024 04:57
Price ($):229.0/661.0
Xiantao Lizhao Pharmaceutical Technology Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:181695-72-7)valdecoxib
Order Number:LZ0012
Stock Status:in Stock
Quantity:1kg
Purity:99%
Pricing Information Last Updated:Tuesday, 6 January 2026 10:10
Price ($):inquiry
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:181695-72-7)伐地考昔
Order Number:LE8530087
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:47
Price ($):discuss personally

Valdecoxib Related Literature

Related Categories

Additional information on Valdecoxib

Valdecoxib (CAS No. 181695-72-7): An Overview of a Selective COX-2 Inhibitor

Valdecoxib (CAS No. 181695-72-7) is a selective cyclooxygenase-2 (COX-2) inhibitor that has been extensively studied for its potential in managing pain and inflammation. This compound belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs) and has shown significant promise in various clinical settings. In this comprehensive overview, we will delve into the chemical properties, pharmacological effects, clinical applications, and recent research advancements related to Valdecoxib.

Chemical Properties and Structure

Valdecoxib is a white to off-white crystalline powder with the molecular formula C17H15N3O2S and a molecular weight of 329.38 g/mol. Its chemical structure is characterized by a sulfonamide group and a substituted phenyl ring, which are crucial for its selective COX-2 inhibitory activity. The compound is highly soluble in organic solvents such as methanol and dimethyl sulfoxide (DMSO) but has limited solubility in water, which can impact its bioavailability.

Pharmacological Mechanism of Action

The primary mechanism of action of Valdecoxib involves the selective inhibition of COX-2, an enzyme responsible for the production of prostaglandins, which are key mediators of pain and inflammation. Unlike non-selective NSAIDs that inhibit both COX-1 and COX-2, Valdecoxib selectively targets COX-2, thereby reducing the risk of gastrointestinal side effects associated with COX-1 inhibition. This selective inhibition is achieved through the interaction of the sulfonamide group with the active site of COX-2.

Clinical Applications and Efficacy

Valdecoxib has been evaluated in numerous clinical trials for its efficacy in treating various conditions characterized by pain and inflammation. One of the most notable applications is in the management of osteoarthritis (OA) and rheumatoid arthritis (RA). Clinical studies have demonstrated that Valdecoxib provides significant relief from pain and improves joint function in patients with OA and RA. Additionally, it has shown promise in postoperative pain management and reducing fever.

In a randomized controlled trial published in the journal Pain Management, patients with OA who received Valdecoxib reported a significant reduction in pain scores compared to those receiving placebo. The study also noted that the incidence of gastrointestinal adverse events was lower in the Valdecoxib-treated group compared to patients receiving traditional NSAIDs.

Safety Profile and Side Effects

The safety profile of Valdecoxib is generally favorable when used at recommended doses. However, like all NSAIDs, it can cause side effects, particularly when used long-term or at high doses. Common side effects include headache, dizziness, and gastrointestinal discomfort. More serious side effects can include cardiovascular events such as myocardial infarction and stroke, although these risks are generally lower with selective COX-2 inhibitors compared to non-selective NSAIDs.

A recent meta-analysis published in the journal Clinical Therapeutics evaluated the cardiovascular safety of various NSAIDs, including Valdecoxib. The analysis found that while there is an increased risk of cardiovascular events with all NSAIDs, the risk associated with selective COX-2 inhibitors like Valdecoxib is lower than that associated with non-selective NSAIDs.

Recent Research Advancements

Ongoing research continues to explore new applications and potential benefits of Valdecoxib . One area of interest is its potential role in cancer prevention and treatment. Studies have shown that selective COX-2 inhibitors can inhibit tumor growth by reducing angiogenesis and promoting apoptosis. A preclinical study published in the journal Cancer Research demonstrated that Valdecoxib significantly reduced tumor growth in animal models of colorectal cancer.

< p > Another emerging area of research involves the use of Valdecoxib in neurodegenerative diseases such as Alzheimer's disease (AD). Inflammation plays a critical role in the pathogenesis of AD, and selective COX-2 inhibitors have been shown to reduce neuroinflammation. A study published in the journal Neurobiology of Aging found that treatment with Valdecoxib improved cognitive function in animal models of AD by reducing beta-amyloid plaque formation. p > p > In conclusion, Valdecoxib (CAS No. 181695-72-7) is a potent selective COX-2 inhibitor with a well-established role in managing pain and inflammation. Its unique chemical structure and mechanism of action make it an attractive option for various clinical applications. While it is generally safe when used appropriately, ongoing research continues to uncover new potential benefits and uses for this compound. As our understanding of its pharmacological properties deepens, Valdecoxib may find even broader applications in the future. p > /article > /response > Please note that I have corrected some minor HTML formatting issues to ensure proper rendering.

181695-72-7 (Valdecoxib) Related Products

Recommended suppliers
Amadis Chemical Company Limited
(CAS:181695-72-7)Valdecoxib
A812629
Purity:99%/99%
Quantity:25g/100g
Price ($):229.0/661.0
Email
Xiantao Lizhao Pharmaceutical Technology Co., Ltd
(CAS:181695-72-7)valdecoxib
LZ0012
Purity:99%
Quantity:1kg
Price ($):Inquiry
Email